Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06801834 by Gilead Sciences, with 695 participants planned, started 2025-04-04 and due to reach its primary completion in 2029-10. Interventions recorded: Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available). Conditions listed: Extensive Stage Small Cell Lung Cancer (ES-SCLC). No results are recorded here; the registry entry is the source.